ISO 14155:2026
Clinical investigation of medical devices for human subjects — Good clinical practice
Standard Introduction
ISO 14155:2026 is the current fourth edition of the international good clinical practice standard for human clinical investigations of medical devices. Published on 23 March 2026, it replaced ISO 14155:2020 and covers investigation design, conduct, recording and reporting used to evaluate clinical performance, effectiveness and safety.
The edition strengthens participant protection, residual and procedure-related risk assessment, data monitoring, clinical events review, adverse-event reporting, estimands, missing-data planning and follow-up. ISO has already registered a fifth-edition work item, but it is only at an early development stage; ISO 14155:2026 remains the published current edition.
Medical-Device GCP
Sets good clinical practice for designing, conducting, recording and reporting human clinical investigations that evaluate medical-device clinical performance, effectiveness and safety.
Participant and Evidence Protection
Combines participant rights, safety and well-being with scientifically sound investigation design, reliable data and credible results for regulatory and conformity-assessment use.
Fourth-Edition Changes
The 2026 edition strengthens residual-risk assessment, procedure-related risk management, data monitoring, clinical events review, adverse-event reporting, estimands, missing-data planning and follow-up.
list_alt Core Investigation Controls
- Ethics review and informed consent
- Clinical investigation plan objectives, design and endpoints
- Sponsor and principal-investigator responsibilities
- Device-use and clinical-procedure risk management
- Data monitoring and clinical events committee decisions
- Electronic clinical data and record integrity
- Adverse-event and device-deficiency assessment and reporting
- Suspension, termination, follow-up and final reporting
Who Needs to Comply?
Medical-device manufacturers and sponsors planning human clinical investigations; principal investigators and investigation sites; contract research organizations; ethics committees; data, statistics and safety teams; and service providers supporting clinical evidence. The standard can be applied as relevant to post-market investigations and Software as a Medical Device. It does not directly apply to in vitro diagnostic devices, although national or regional rules may make selected provisions relevant.
Key Requirements
Ethics and Informed Consent
Obtain the required ethics approval and informed consent before investigation procedures, protect subjects' rights and well-being, and account for legally designated representatives and meaningful opportunities to discuss participation where applicable.
Investigation Design and Statistical Planning
Define clinically relevant objectives, endpoints, comparators, eligibility criteria, methods and analysis. Address estimands, non-inferiority margins, missing data, equipment calibration and stopping conditions in proportion to the investigation.
Risk Management
Distinguish risks from use of the investigational device from risks introduced by clinical procedures outside routine practice, assess residual risks, define controls and connect investigation decisions to ISO 14971 risk management.
Oversight Committees
Define whether a data monitoring committee and clinical events committee are needed, document independence and responsibilities, and establish review, adjudication, escalation, suspension or stopping rules.
Data and Safety Records
Maintain traceable electronic and paper records, protect confidentiality, control access and changes, document device deficiencies and adverse events, and apply the applicable reduced or full reporting pathways.
Sponsor, Investigator and Follow-Up Duties
Document delegated activities without losing accountability, control the investigational device, train users, monitor sites, manage suspension or early termination, provide necessary follow-up and continued care, and issue an accurate clinical investigation report.
Implementation Roadmap
Confirm investigation and market scope
Identify the investigational device, intended purpose, development stage, target populations, sites and jurisdictions. Confirm whether the work is pre-market, post-market or SaMD-related, and record applicable law, ethics rules, regulator guidance and conformity-assessment expectations alongside ISO 14155:2026.
Run a 2020-to-2026 gap review
Compare controlled procedures and templates with the fourth edition. Prioritize eligibility deviations, informed consent, procedure-related risks, residual-risk assessment, data monitoring and clinical events committees, adverse-event pathways, estimands, missing data, implant cards and subject follow-up.
Design the investigation and oversight
Finalize the clinical investigation plan, statistical analysis approach, risk controls, monitoring strategy, committee charters, event-adjudication rules, suspension criteria, data flows, equipment calibration and sponsor-investigator-service-provider responsibilities.
Approve, train and initiate
Obtain ethics and regulatory approvals, verify informed-consent materials, qualify sites and systems, train investigators and users, control investigational devices, test escalation paths and confirm that essential records can reconstruct decisions and data changes.
Monitor, report and close
Monitor conduct and data quality, assess adverse events and device deficiencies, operate oversight committees, manage amendments or suspension, preserve follow-up and continued-care decisions, reconcile devices and records, analyse results and issue the clinical investigation report.
Compliance Checklist
checklist Applicability and governance
checklist Design, risk and statistics
checklist Participants and conduct
checklist Data, safety and closure
ISO 14155:2020 to 2026 transition focus
Use the official redline or controlled standard text for clause-level work; this table identifies the operational areas that need review.
| Review area | 2026 focus | Implementation evidence |
|---|---|---|
| Risk management | Separates device-use and procedure-related risks and strengthens residual-risk assessment | Risk analysis, control decisions and benefit-risk records |
| Oversight | Strengthens DMC stopping conditions and adds clinical events committee provisions | Committee rationale, charters, independence and decisions |
| Statistics | Adds estimand concepts and clarifies non-inferiority and missing-data planning | CIP and statistical analysis plan rationale |
| Safety reporting | Clarifies event categories, reduced-reporting situations and suspension processes | Event records, adjudication, notifications and escalation logs |
| Participants | Clarifies representatives, discussion opportunities, follow-up and continued care | Consent materials, follow-up plans and care records |
| Device and procedure records | Adds implant-card, calibration, training and in-silico considerations | Device accountability, calibration, training and justification records |
Common Misconceptions
ISO 14155 is the same as ICH E6.
Both address good clinical practice, but ISO 14155 is specific to medical-device investigations. ICH E6 primarily addresses clinical trials intended for medicines-regulatory use.
Following the 2020 edition is enough because the new edition is already under revision.
ISO 14155:2020 is withdrawn. The fifth edition is only an early work item, so ISO 14155:2026 is the current published edition.
A signed consent form is the complete informed-consent process.
Consent also requires approved information, appropriate discussion, voluntariness, timing and use of a legally designated representative where applicable.
Only risks caused directly by the device belong in the investigation plan.
The 2026 edition also emphasizes risks introduced by clinical procedures required by the investigation plan when those procedures are outside routine practice.
Penalties & Enforcement
ISO 14155:2026 is a voluntary International Standard and is not a standalone certification or penal regime. Regulators, ethics committees, notified bodies, contracts or national law may require or recognize its practices. Weak subject protection, investigation conduct or evidence can lead to ethics findings, corrective action, investigation suspension, unusable data, delayed or refused regulatory decisions, and jurisdiction-specific enforcement.
Frequently Asked Questions
What is ISO 14155:2026?
expand_more
ISO 14155:2026 is the fourth edition of the international good clinical practice standard for designing, conducting, recording and reporting human clinical investigations of medical devices. ISO published it on 23 March 2026 and withdrew the 2020 edition.
Is ISO 14155:2026 mandatory?
expand_more
Not by itself. It is a voluntary International Standard, but regulators, ethics committees, notified bodies, contracts or national rules can require or recognize its practices. Organizations must verify the legal and conformity-assessment framework in every investigation market.
Does ISO 14155 apply to post-market clinical investigations?
expand_more
Its principles are intended to be followed as far as relevant to the purpose, design and nature of the post-market investigation. The applicability decision and any mandatory requirements also depend on national or regional rules.
Does ISO 14155 apply to SaMD and IVDs?
expand_more
For Software as a Medical Device, the requirements apply as far as relevant to the clinical investigation and the evidence being generated. The standard does not directly apply to in vitro diagnostic devices, although a jurisdiction can make selected provisions relevant.
What changed from ISO 14155:2020?
expand_more
The fourth edition clarifies eligibility, informed consent, clinical performance, adverse-event reporting and suspension. It strengthens residual and procedure-related risk assessment, data monitoring, clinical events committees, statistical estimands, missing-data planning, implant cards, equipment calibration and follow-up.
Can a company be certified to ISO 14155?
expand_more
ISO 14155 is not an organizational management-system certification standard. Investigation compliance is evaluated through ethics and regulatory oversight, sponsor monitoring, audits, inspections, conformity assessment and review of the clinical evidence.
Is ISO 14155:2026 already being replaced?
expand_more
It remains the published current edition. ISO registered a fifth-edition approved work item on 22 June 2026 at Stage 20.00, which means a revision is under early development; it is not a published replacement.
Official Documentation
Official PDF for ISO 14155:2026
Official publication or summary for ISO 14155:2026
Official online resource
International Organization for Standardization (ISO) guidance and reference material
Implementation toolkit
Templates, guidance, or companion resources for ISO 14155:2026